TN2014000147A1 - Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique - Google Patents

Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique

Info

Publication number
TN2014000147A1
TN2014000147A1 TNP2014000147A TN2014000147A TN2014000147A1 TN 2014000147 A1 TN2014000147 A1 TN 2014000147A1 TN P2014000147 A TNP2014000147 A TN P2014000147A TN 2014000147 A TN2014000147 A TN 2014000147A TN 2014000147 A1 TN2014000147 A1 TN 2014000147A1
Authority
TN
Tunisia
Prior art keywords
phenylimidazol
sodium channel
derivatives useful
channel modulators
ethylamine derivatives
Prior art date
Application number
TNP2014000147A
Other languages
English (en)
French (fr)
Inventor
Sharanjeet Kaur Bagal
Mark Ian Kemp
Duncan Charles Miller
Yoshihisa Murata
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000147(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of TN2014000147A1 publication Critical patent/TN2014000147A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2014000147A 2011-10-26 2014-04-08 Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique TN2014000147A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (1)

Publication Number Publication Date
TN2014000147A1 true TN2014000147A1 (fr) 2015-09-30

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2014000147A TN2014000147A1 (fr) 2011-10-26 2014-04-08 Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique

Country Status (28)

Country Link
US (1) US9079878B2 (cg-RX-API-DMAC10.html)
EP (1) EP2771335A2 (cg-RX-API-DMAC10.html)
JP (1) JP5946538B2 (cg-RX-API-DMAC10.html)
KR (1) KR101586966B1 (cg-RX-API-DMAC10.html)
CN (1) CN103906746B (cg-RX-API-DMAC10.html)
AP (1) AP2014007579A0 (cg-RX-API-DMAC10.html)
AU (1) AU2012328034B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014009102A2 (cg-RX-API-DMAC10.html)
CA (1) CA2850925C (cg-RX-API-DMAC10.html)
CL (1) CL2014000956A1 (cg-RX-API-DMAC10.html)
CO (1) CO6940427A2 (cg-RX-API-DMAC10.html)
CR (1) CR20140185A (cg-RX-API-DMAC10.html)
CU (1) CU20140046A7 (cg-RX-API-DMAC10.html)
DO (1) DOP2014000085A (cg-RX-API-DMAC10.html)
EA (1) EA023375B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP14013324A (cg-RX-API-DMAC10.html)
GT (1) GT201400079A (cg-RX-API-DMAC10.html)
IL (1) IL232267A (cg-RX-API-DMAC10.html)
MD (1) MD20140037A2 (cg-RX-API-DMAC10.html)
MX (1) MX337469B (cg-RX-API-DMAC10.html)
NI (1) NI201400031A (cg-RX-API-DMAC10.html)
PE (1) PE20141682A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014500919A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201401032YA (cg-RX-API-DMAC10.html)
TN (1) TN2014000147A1 (cg-RX-API-DMAC10.html)
UA (1) UA109220C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013061205A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201402281B (cg-RX-API-DMAC10.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145428B2 (en) * 2011-09-14 2015-09-29 Dow Agrosciences Llc Methods and systems for forming boronic acids and intermediates thereof
SG11201604477SA (en) 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
CN107206015A (zh) 2014-10-24 2017-09-26 阿维塔斯有限公司 透细胞质膜的传递
AU2016219879A1 (en) 2015-02-19 2017-08-24 Purdue Pharma L.P. Methods and compositions for decreasing gastric emptying
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
EP3397760A2 (en) 2015-12-30 2018-11-07 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
EP3481857B1 (en) 2016-07-06 2026-02-11 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
EP4650364A3 (en) 2016-07-06 2026-01-21 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
KR102714561B1 (ko) 2017-05-16 2024-10-10 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
GEAP202315648A (en) 2018-11-02 2023-07-25 Merck Sharp & Dohme Llc 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
SMT202600064T1 (it) 2021-06-04 2026-03-09 Vertex Pharma Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US20240368135A1 (en) 2021-06-04 2024-11-07 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
IL316422A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for pain treatment
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CA3256486A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic Na V1.8 Heterocyclic Amide Inhibitors for Pain Management
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
KR20250120351A (ko) 2022-12-06 2025-08-08 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법
KR20260116140A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
KR20260116141A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료용 화합물 및 이의 고체 형태의 제조방법
KR20260118418A (ko) 2023-10-23 2026-07-30 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
AU2024393245A1 (en) 2023-12-07 2026-06-18 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
AU2025211735A1 (en) 2024-01-24 2026-07-16 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors
TW202606663A (zh) 2024-06-28 2026-02-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
LU605402B1 (en) 2024-07-11 2026-07-14 Sea4Us Biotecnologia E Recursos Marinhos Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AP2353A (en) * 2004-05-07 2012-02-16 Warner Lambert Co 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands.
WO2006047687A2 (en) 2004-10-27 2006-05-04 Schering Corporation Compositions and methods for short interfering nucleic acid inhibition of nav1.8
IN266803B (cg-RX-API-DMAC10.html) 2005-12-22 2015-06-03 Newron Pharm Spa
GEP20125425B (en) 2006-10-18 2012-03-26 Pfizer Prod Inc Biaryl ether urea compounds
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
US20100227872A1 (en) * 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
EA015952B1 (ru) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
JP5460589B2 (ja) 2007-07-13 2014-04-02 アイカジェン, インコーポレイテッド ナトリウムチャネル阻害物質

Also Published As

Publication number Publication date
AU2012328034A1 (en) 2014-05-15
PE20141682A1 (es) 2014-11-14
GT201400079A (es) 2015-06-02
UA109220C2 (uk) 2015-07-27
EA201490864A1 (ru) 2014-08-29
EA023375B1 (ru) 2016-05-31
MD20140037A2 (ro) 2014-08-31
MX2014004738A (es) 2014-08-01
WO2013061205A2 (en) 2013-05-02
NI201400031A (es) 2014-10-01
JP2014530900A (ja) 2014-11-20
KR101586966B1 (ko) 2016-01-19
CN103906746A (zh) 2014-07-02
IL232267A (en) 2016-10-31
PH12014500919A1 (en) 2014-06-09
CA2850925C (en) 2017-01-10
DOP2014000085A (es) 2014-08-31
BR112014009102A2 (pt) 2017-04-18
AP2014007579A0 (en) 2014-04-30
EP2771335A2 (en) 2014-09-03
CU20140046A7 (es) 2014-10-02
ECSP14013324A (es) 2014-05-31
WO2013061205A3 (en) 2013-06-27
CO6940427A2 (es) 2014-05-09
NZ623090A (en) 2015-10-30
CL2014000956A1 (es) 2014-07-18
WO2013061205A8 (en) 2014-03-27
US20140296313A1 (en) 2014-10-02
HK1198650A1 (en) 2015-05-22
CN103906746B (zh) 2015-12-09
CR20140185A (es) 2014-06-03
IL232267A0 (en) 2014-06-30
CA2850925A1 (en) 2013-05-02
KR20140069234A (ko) 2014-06-09
MX337469B (es) 2016-03-02
ZA201402281B (en) 2015-11-25
US9079878B2 (en) 2015-07-14
AU2012328034B2 (en) 2015-04-23
SG11201401032YA (en) 2014-07-30
JP5946538B2 (ja) 2016-07-06

Similar Documents

Publication Publication Date Title
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA32965B1 (fr) Derives de sulfonamides
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA31447B1 (fr) Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA43756B1 (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
PH12014500919A1 (en) (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
MA31419B1 (fr) Derives de pyridine
MA42232B1 (fr) Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant
MA30932B1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
EA201000314A1 (ru) 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны
MA29926B1 (fr) Derives de pyrazine
MA34308B1 (fr) Triazolopyridines substituées
MA31366B1 (fr) Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c